Background. Transforming growth factor-β (TGFβ)-induced epithelial-myofibroblast transdifferentiation is a central mechanism contributing to the pathogenesis of progressive tubulo-interstitial fibrosis. We wanted to dissect the role of extracellular signal-regulated protein kinase (ERK1,2), p38 mitogen-activated protein kinase (p38 MAPK) and the receptor-regulated Smad proteins in the regulation of α-smooth muscle cell actin (αSMA) expression, a hallmark of myofibroblast formation, induced by TGFβ in renal proximal tubular cells. Methods. Activation of signalling molecules was assessed by western blotting using phospho-specific antibodies. To specifically interfere with signalling cascades, porcine proximal tubular cells (LLC-PK/AT1) were infected with recombinant replication-deficient adenoviruses. In other experiments, specific kinase inhibitors were used. The αSMA synthesis was assessed by western blotting or immunofluorescent staining of cellular αSMA. To assess the regulation of the αSMA promoter, tubular cells were transiently transfected with a 785 bp αSMA promoterluciferase reporter construct and vectors interfering with the Smad pathway. caused a substantial inhibition of the TGFβ effect, confirming the role of p38β in the regulation of TGFβ-induced αSMA expression. Finally, inhibiting the Smad pathway with adenovirally delivered Smad7 and DN Smad3 also blocked TGFβ-induced αSMA synthesis. Conclusion. TGFβ-induced αSMA expression is regulated by the coordinated activation of a complex system of parallel MAPK and Smad signalling pathways in renal proximal tubular cells during epithelial-mesenchymal transdifferentiation.
Introduction
Epithelial-mesenchymal transdifferentiation (EMT)-a process known to play an important role during organ development, wound healing and tumour invasion-has recently emerged as a central mechanism in the pathogenesis of tubulo-interstitial fibrosis (TIF) [1] [2] [3] [4] . Pro-fibrotic stimuli induce a coordinated genetic program in the highly differentiated tubular epithelial cells (TEC) that results in profound phenotypic changes [5] . This process is associated with a marked reorganization of the cytoskeleton. Transformed cells become motile and migrate into the interstitium. Some of the transdifferentiating cells express α-smooth muscle cell actin (αSMA) that is completely absent in tubular epithelial cells. The appearance of αSMA in the transdifferentiating cells during EMT is a hallmark of myofibroblast (MF) formation. MFs are thought to play a central role in excessive matrix deposition during the fibrotic process [6, 7] . However, αSMA is more than a marker of this process, as it is instrumental for MF contraction and force generation for tissue retraction-an important feature of the fibrotic process [6, 7] .
Transforming growth factor-β (TGFβ) is a central regulator of the pathogenesis of TIF and it is also one of the most potent growth factors to induce EMT in tubular cells [8] . TGFβ induces EMT through a complex interplay of signalling pathways, the exact details of which have still not been fully elucidated. In different cellular systems, the Smad proteins [9, 10] , the Rho-family GTPases [11, 12] , the extracellular signal-regulated protein kinase (ERK1,2) [5, 13] and the p38 mitogen-activated protein kinase (MAPK) [14] have all been shown to contribute to the induction of EMT by TGFβ.
The p38 MAPK family consists of four isoforms: p38α, p38β, p38γ and p38δ [15] . Recently, it has been demonstrated that different p38 isoforms may have different functions [16] . It is currently not known which p38 isoform is involved in the regulation of TGFβ-induced EMT in renal tubular cells. This could potentially have important implications as the different isoforms can specifically be inhibited using newly developed isoform-specific inhibitors.
Several studies have demonstrated that TGFβ induces de novo SMA synthesis in renal tubular cells during EMT [12, 17] . SMA expression by TGFβ is regulated at least in part at the transcriptional level. Regulation of the SMA transcription is remarkably complex and shows substantial tissue specificity. In different cellular systems, both the Smad proteins and members of the MAPK family are known to regulate αSMA transcription [9, 18] .
We have previously shown, using LLC-PK1 porcine proximal tubular cells, that several signalling systems were indispensable for the TGFβ and cell-contact disassemblyinduced EMT [12, 19] . Here we report results of experiments that were designed to study the role of ERK1,2, p38 MAPK and the receptor-regulated Smad proteins (RSmad) in the αSMA protein expression induced by TGFβ using LLC-PK1 porcine renal proximal tubular cells, the same cellular model system that we had used in our earlier work. The αSMA in LLC-PK1 cells was first seen after 24 h of incubation with TGFβ, with a further increase during the subsequent 72 h. TGFβ induced a biphasic activation of ERK1,2 and p38, as well as Smad2 and Smad3. Inhibition of both ERK1,2 and p38β MAPK blocked the effect of TGFβ on αSMA protein synthesis. Furthermore, inhibition of Smad signalling with Smad7 or dominant negative (DN) Smad3 also inhibited TGFβ-induced SMA protein expression in tubular cells. Together, these observations provide evidence for the coordinated role of MAPK and Smad signalling pathways in mediating the phenotypic alterations of renal tubular cells in response to TGFβ.
Material and methods

Cell culture
Porcine proximal tubular epithelial cells stably expressing the rabbit AT1 receptor (LLC-PK1/AT1) were grown in Dulbecco's modified Eagle's medium (DMEM, Sigma, St Louis, MO, USA) supplemented with 10% fetal calf serum (FCS), 2 mM L-glutamine, 100 IU/ml penicillin G and 100 µg/ml streptomycin in a humidified incubator at 37
• C and 5% CO 2 .
Reagents and antibodies
Human recombinant TGFβ1 was obtained from Sigma (St Louis, MO, USA), and the p38 inhibitor SB203580 and the MEK inhibitor PD98059 were from Calbiochem (San Diego, CA, USA). Anti-αSMA (1A4) and anti-FLAG antibodies were purchased from Sigma. Anti-phospho-p38, anti-p38, antiphospho-ERK1/2 and anti-ERK1/2 antibodies were from Cell Signaling Technology (Beverly, MA, USA). Antisera against phospho-Smad2 (PS2) and phospho-Smad1 (PS1), which show cross-reactivity with phosphorylated Smad3, were kind gifts from Dr A. Moustakas (Ludwig Institute for Cancer Research, Uppsala, Sweden) [10] . Polyclonal Smad2 and Smad3 antibodies were from Zymed Laboratories Inc. (San Francisco, CA, USA), and rat monoclonal anti-HA 3F10 antibody was from Roche Molecular Biochemicals, Mannheim, Germany. Anti-mouse antibody was obtained from Amersham Biosciences (Uppsala, Sweden), anti-rabbit IgG was from DAKO, Glostrup, Denmark and anti-rat antibody was from Santa Cruz Biotechnology (San Francisco, CA, USA). The antibodies for immunostaining anti-rat-rhodamine and anti-mouse IgG, heavy and light chain fluorescein conjugates were from Calbiochem.
Plasmids and transient transfection
The PA3-Luc vector containing a 765 bp fragment of the rat SMA promoter was a kind gift from Dr R.A. Nemenoff (Department of Medicine, University of Colorado, CO, USA). The pSmad7 expression construct was a kind gift from Dr E.P. Böttinger (Albert Einstein College of Medicine, Bronx, NY, USA) [20] . The vector encoding DN Smad3 was described and used in our previous work. The thymidine kinase-driven Renilla luciferase vector (pRL-TK; Promega, Madison, WI, USA) was used as an internal control.
LLC-PK1/AT1 cells were grown on six-well plates and transfected at 50% confluence with 2.5 µl FuGene6 (Roche) reagent using 0.5 µg pSMA-Luc, 0.05 µg pRL-TK and 2 µg of interfering plasmid or pcDNA3. Sixteen hours later the cells were washed three times with PBS and the medium was replaced with serum-free DMEM. Six hours later 5 ng/ml TGFβ or its vehiculum was added for 20 h. Cells were then lysed in 500 µl passive lysis buffer (Promega) and the samples were subjected to freezing/thawing. Firefly and Renilla luciferase activities were measured with the Dual Luciferase Reporter Assay Kit (Promega) following the instructions of the manufacturers. Results were normalized to the values obtained by the Renilla measurements for each sample.
Reverse transcription PCR (RT-PCR) analysis of p38
isoform expression [21, 22] Total cellular RNA was extracted from cultured cells using the Qiagen RNeasy Mini kit (Qiagen Nordic, Helsinki, Finland) according to the manufacturer's instructions. The cDNA was synthesized using 1 µg RQ1 RNase-free DNasetreated RNA, M-MLV reverse transcriptase, RNase inhibitor and random hexamer primers (all reagents were from Promega). The final RT reaction mix was 20 µl and the program was as follows: 15 min at 42
• C, 5 min at 99
• C and 5 min at 5
• C. PCR reaction was carried out by using the DyNAzyme EXT kit (Finnzymes, Espoo, Finland) according to the manufacturer's instructions. Briefly, all samples were prepared by mixing in 50 µl final volume, 5 µl optimized DyNAzyme EXT buffer, 1 µl dNTPs (200 µM), 1 µM forward and reverse primers and 1 µl DyNAzyme (1U). The following program was used: 2 min at 94
• C, and then: (30 s at 94
• C, 30 s at 55
• C and 60 s at 72
• C) × 34 times followed by 10 min at 72
• C at the end. The sequences of the primers were as follows:
p38α: fwd 5 -AAC CTG TCT CCA GTG GGC TCT-3 ; rev 3 -CGT AAC CCC GTT TTT GTG TCA-5 ; p38β: fwd 5 -CAC CCA GCC CTG AGG TTC T-3 ; rev 3 -AGA TGC TGC TCA GGT CCT TCT-5 ; p38γ: fwd 5 -CGC CTC CGG GCT GAG TTT-3 ; rev 3 -GCT TGC ATT GGT CAG GAT AGA-5 ; p38δ: fwd 5 -TGC TCG GCC ATC GAC AA-3 ; rev 3 -TGG CGA AGA TCT CGG ACT GA-5 ; β-actin: fwd 5 -TCA CCC ACA ctg tgc cca tct acg c-3 ; rev 3 -cag cgg aac cgc tca ttg cca atg g-5 .
Specificity of amplification was confirmed by running each amplicon on a 3% agarose gel and obtaining a single band of the expected size (p38α-70 bp, p38β-98 bp, p38γ-105 bp and p38δ-81 bp). The gel contained a final concentration of 0.5 µg/ml ethidium bromide. Expression of β-actin was used as control.
Recombinant adenoviruses
Recombinant replication-deficient adenovirus RAdLacZ, which contains the Escherichia coli β-galactosidase gene under the control of the cytomegalovirus immediate early promoter, was kindly provided by Dr Gavin W.G. Wilkinson (University of Cardiff, Wales, UK). Recombinant adenovirus for DN Smad3 (RAdSmad3DN) [10] and the SMAD7 adenovirus were kindly provided by Dr A. Moustakas (Ludwig Institute for Cancer Research, Uppsala, Sweden), and adenovirus for constitutively active (CA) MEK1 (RAdMEK1CA) was provided by Dr M. Foschi (University of Florence). Adenoviruses for CA MKK3b (RAdMKK3bE), CA MKK6b (RAdMKK6bE), DN p38α (RAdp38αAF) and DN p38β (RAdp38βAF), DN MKK3b (RAdMKK3bA) and MKK6b (RAdMKK6bA) were all kindly provided by Dr Jiahua Han (Scripps Research Institute, La Jolla, CA, USA). Replication-deficient (E1-and E3-) adenoviruses RAdSmad2, RAdSmad3 harbouring human Smad2 and Smad3 cDNAs, respectively, with an N-terminal haemagglutinin (HA) tag, were described previously [23] .
Infection of cells with recombinant adenoviruses
Cells were infected in suspension with the adenoviruses at 1 MOI in DMEM with 1% FCS, and then plated and incubated for 18 h. Subsequently, the medium was replaced with fresh 1% FCS DMEM. Six hours later, 5 ng/ml TGFβ was added for the time indicated. The cells then were harvested in SDS sample buffer and analysed by western blotting.
Western blotting
LLC-PK1/AT1 cells were plated onto 6-cm dishes and grown until confluent. After washing the cells with PBS, the medium was replaced with serum-free DMEM for 24 h. Subsequently 5 ng/ml TGFβ was added. In some experiments, the cells were pretreated with 1 and 5 µM SB203580 and 40 µM PD98059. At the time indicated, cells were harvested into SDS sample buffer.
Cell lysates were fractionated on 12% SDSpolyacrylamide gel and transferred to the Hybond ECL nitrocellulose membrane (Amersham Biosciences). The membranes were blocked with 5% skim milk. After ample washing, specific primary antibodies and subsequently peroxidase-conjugated secondary antibodies were added. The blots were visualized by the ECL detection system (Amersham Biosciences).
Immunostaining
Cells were pretreated with SB203580 and PD98059, and treated with TGFβ. After 4 days of incubation, medium was removed, the cells were washed with ice-cold PBS, fixed with −20
• C methanol and incubated at -20 • C for 6 min. After washing in PBS, the cells were stained with the appropriate primary and secondary antibodies, and Hoechst reagent. The results were visualized by a Leica fluorescence microscope.
Statistical analysis
Experiments were repeated at least three times. For western blot and immunostaining experiments, representative images are shown. Transfections were performed in duplicates. The results are shown as mean ± SD and expressed as a ratio of the luciferase activity in the TGFβ-treated groups compared to the vehicle-treated groups (fold stimulation). One-way ANOVA was used to analyse the data.
Results
TGFβ activates multiple signalling pathways in LLC-PK1 tubular cells
In different cellular systems, both ERK1,2, p38 MAPK and the Smad proteins were shown to contribute to the induction of EMT by TGFβ. In our proximal tubular cells, TGFβ induced phosphorylation, i.e. activation of both ERK1,2 and p38 MAPK ( Figure 1A ). The phosphorylation of these proteins was somewhat delayed, especially for p38 MAPK, for which increased phosphorylation was first seen at 60 min after stimulation. Furthermore, the initial activation of p38 was transient, the activity declining close to baseline within 2 h. In contrast, increased phosphorylation of ERK1,2 was more prolonged, the phosphorylation remaining increased throughout the first 3 h of incubation.
Interestingly, phosphorylation, that is, activation of Smad2 and Smad3, was more rapid ( Figure 1A ). For both LLC-PK/AT1 cells plated on 6-cm dishes were treated with vehicle or 5 ng/ml TGFβ for the indicated times. Western blots were performed with anti-phospho-specific antibodies for pSmad2, pSmad3, pERK1,2 and pp38 (see the Materials and methods section). To demonstrate equal loading, the membrane was re-probed for total p38 MAPK. these proteins, an increased phosphorylation was seen as early as 15 min after the addition of TGFβ to the medium, and the maximum effect was seen at 60 min. This effect was transient for both proteins, with a more rapid decline of the phosphorylation for Smad3.
TGFβ induces a biphasic increase in MAPK and Smad phosphorylation in LLC-PK1 cells
Expression of αSMA was not seen until 24-48 h of TGFβ exposure and reached a maximum after 3-4 days of incubation (not shown). Therefore, we analysed the effect of prolonged (up to 4 days) TGFβ treatment on R-Smads and MAP kinases in LLCPK1/AT1 cells ( Figure 1B) . TGFβ activated these signalling proteins with a markedly different time course. Activation of Smad3 was quite transient, with essentially no further activation seen after 4 h of stimulation with TGFβ. On the other hand, the phosphorylation of ERK1,2, p38 MAPK and Smad2 followed a biphasic pattern. After the initial peak at 1 h, the activation returned towards baseline for all three proteins but began to rise again thereafter. For Smad2 and ERK1,2, the phosphory- lation remained significantly increased even during the intermediate period and started to increase again after 12-24 h of TGFβ incubation. The phosphorylation of these signalling proteins remained increased until the end of the 4-day incubation period. For p38 MAPK, however, the activation returned close to the baseline by the fourth hour and the second peak started quite late at 24-48 h ( Figure 1B) . The phosphorylation level of these signalling molecules remained at or below baseline during the incubation period in quiescent control cells without TGFβ stimulation (not shown).
Both ERK1,2 and p38 MAPKs contribute to the TGFβ-induced αSMA synthesis in renal tubular cells
To assess the functional significance of the ERK1,2 signalling pathway in TGFβ-induced αSMA synthesis, the specific MEK1 inhibitor PD98059 was used. Alpha SMA synthesis was assessed by western blotting and immunofluorescent staining of cellular SMA. Treatment of cells with TGFβ for 96 h resulted in the induction of αSMA ( Figure  2A ) and in marked alteration in the morphology of the cells ( Figure 2B) . Pretreatment of the cells with PD98059 potently inhibited the TGFβ-induced αSMA synthesis ( Figure  2A ) and also blocked the formation of actin fibres ( Figure  2B) .
Treatment of the cells with SB 203580, a specific inhibitor of p38 MAPK, also inhibited αSMA protein expression. This effect was already seen with a concentration as low as 1 µM, and 5 µM SB203580 blocked the TGFβ effect on αSMA protein expression completely (Figure 2A) . Furthermore, SB203580 also prevented the incorporation of αSMA into the thick actin fibres that were formed upon TGFβ treatment ( Figure 2B ).
TGFβ activates αSMA expression through MKK6 -p38β
As SB203580 is reported to inhibit the activity of p38α and p38β but not p38γ or p38δ isoforms [24] , (therefore, we wanted to determine whether both the α and β isoforms played a role in the TGFβ-induced αSMA expression. To this end, LLC-PK/AT1 cells were infected with replicationdeficient adenoviral vectors expressing the DN mutant of p38α and p38β ( Figure 3A) . A 4-day incubation in the presence of TGFβ induced marked αSMA protein expression in tubular cells infected with the control adenovirus, RAdLacZ. Dominant inhibitory p38α caused a slight decrease in the effect of TGFβ, whereas adenoviral expression of DN p38β inhibited αSMA expression almost completely. No further increase in the inhibitory effect of DN p38β was seen when the cells were infected with both DN p38α and DN p38β together ( Figure 3A) .
Activation of the p38 MAPK occurs through phosphorylation by specific upstream protein kinase kinases, namely MKK3 and MKK6. MKK3 activates p38α, p38δ and possibly p38γ; however, MKK6 activates all four isoforms. To explore the role of these kinases in the increased αSMA expression, we also exploited adenoviral gene delivery of mutated signalling molecules. Infection of the cells with a vector harbouring DN MKK6b caused a substantial inhibition of the TGFβ effect ( Figure 3A) . On the other hand, DN MKK3b, which is expected to inhibit all p38 MAPK isoforms except p38β, had no significant effect on the increased αSMA expression induced by TGFβ. These results together point towards the predominant contribution of p38β to the TGFβ-induced αSMA expression. In concert with the above results, we detected the expression of both p38β and p38δ but not p38α or p38γ in LLC-PK1 cells using RT-PCR analysis ( Figure 3B) .
To test the effect of prolonged activation of ERK1,2 and p38 MAPK on αSMA protein expression, tubular cells were infected with CA MAP kinase kinases (Figure 4) . Active MEK1 induced a marked phosphorylation of ERK1,2 but not of p38 MAPK. In cells infected with CA MKK3, a modest phosphorylation of p38 MAPK was seen, possibly corresponding to the presence of the p38δ isoform. CA MKK6, on the other hand, induced a robust phosphorylation of the endogenous p38 MAPK, suggesting the more Fig. 3 (A) TGFβ activates αSMA expression through MKK6-p38β. LLC-PK1/AT1 cells were infected in suspension with adenoviruses interfering with the p38 MAPK pathway (1 MOI). Twenty-four hours later, 5 ng/ml TGFβ was added for 4 days. The cells then were harvested in SDS sample buffer and analysed by western blotting using anti-αSMA antibody. Subsequently the membrane was re-probed with anti-β-actin antibody as loading control (ctrl virus: empty control virus; DNp38α: dominant negative p38α; DNp38β: dominant negative p38β; DNMKK3: dominant negative MKK3; DNMKK6: dominant negative MKK6). (B) Reverse transcription PCR (RT-PCR) analysis of p38 MAPK isoform expression. Total cellular RNA was extracted from cultured cells and cDNA was synthesized using reverse transcription. PCR reaction was carried out by using isoformspecific primers. Expression of the p38 MAPK isoforms was assessed by running each amplicon on a 3% agarose gel and identifying a single band of the expected size (p38α-70 bp, p38β-98 bp, p38γ-105 bp and p38δ-81 bp). Expression of β-actin was used as control (NTC: negative control). significant contribution of the β isoform. None of the CA MAP kinase kinases, however, were able to reproduce the effect of TGFβ on αSMA synthesis. To confirm this finding, we co-infected tubular cells with both CA MAP kinase kinases and wild-type (WT) p38α or p38β. When CA MKK3 and WT p38α were co-infected, a robust activation of p38 MAPK was seen. However, co-infection of MKK3 and p38β together resulted only in a minimal phosphorylation of both endogenous and the recombinant p38 MAPK, confirming the specificity of MKK3 in activating p38α predominantly. CA MKK6, on the other hand, readily activated both p38α and p38β. In spite of the robust phosphorylation of the recombinant p38 MAP kinases in this experiment, αSMA expression was not seen suggesting that activation of p38 MAPK is necessary but not sufficient to induce αSMA expression in tubular cells.
The receptor-regulated Smad proteins are involved in the regulation of the TGFβ-induced αSMA protein expression in renal tubular cells
To assess if the R-Smads, Smad2 or Smad3, contribute to the effect of TGFβ on αSMA protein expression, multiple experimental approaches were utilized. Smad transcriptional activity can specifically be blocked by using dominant inhibitory or DN mutants of the R-Smad proteins. Furthermore, Smad7 also inhibits Smad signalling by preventing the association of the R-Smads with the active type I receptor. First we used transient transfection experiments in which LLC-PK1/AT1 cells were co-transfected with the 785 bp αSMA promoter-luciferase reporter construct and expression vectors encoding Smad7 or DN Smad3, respectively. As shown in Figure 5A , expression of both Smad7 and DN Smad3 inhibited the effect of the cytokine on the αSMA promoter construct.
To confirm the effect of inhibition of Smad signalling on TGFβ-induced αSMA protein synthesis, tubular cells were infected with adenoviral expression vectors encoding Smad7 or DN Smad3, respectively. Over-expression of both Smad7 and DN Smad3 almost completely blocked the TGFβ-induced αSMA protein synthesis in proximal tubular cells ( Figure 5B ) confirming the proposed role of Smad signalling in this effect.
Discussion
In this paper we have shown that in renal proximal tubular cells, both ERK1,2, p38 MAPK and the R-Smads are required for the induction of αSMA expression by TGFβ, a hallmark component of epithelial-myofibroblast transdifferentiation. Furthermore, we have shown for the first time that p38 MAPK is primarily activated via the MKK6-p38β cascade, and the other p38 isoforms are unlikely to contribute significantly to the transcriptional regulation of The Smad pathway contributes to the transcriptional activation of the αSMA promoter induced by TGFβ in renal tubular cells. LLC-PK1/AT1 cells were transiently co-transfected with the PA3-Luc vector containing a 765 bp fragment of the rat SMA promoter, the thymidine kinase-driven Renilla luciferase vector (pRL-TK; Promega) and either a pSmad7 expression construct, a DN Smad3 expression plasmid or with pcDNA3, the empty vector using FuGene6 (Roche) reagent. The cells were treated with 5 ng/ml TGFβ for 20 h. Firefly and Renilla luciferase activities were measured from cell lysates using the Dual Luciferase Reporter Assay Kit (Promega). Results were normalized to values obtained by the Renilla measurements for each sample. Results (mean ± SD) are expressed as fold stimulation by TGFβ in each group. The asterisk indicates that the fold stimulation in the cells co-transfected with the interfering plasmid was significantly less than that in cells co-transfected with the empty vector (pcDNA3) (P < 0.05; n = 6, ANOVA). (B) The Smad pathway contributes to the transcriptional activation of the αSMA promoter induced by TGFβ in renal tubular cells. LLC-PK1/AT1 cells were infected in suspension with recombinant replication-deficient adenoviruses (1 MOI) and were treated with 5 ng/ml TGFβ or vehicle for 4 days. The cells then were harvested in SDS sample buffer and analysed by western blotting for αSMA. Expression of adenovirally delivered FLAG-tagged Smad3DN and Smad7 was verified by western blot with anti-FLAG antibody. Subsequently the membrane was re-probed with anti-β-actin antibody as loading control (ctrl virus: empty control virus; DN SMAD3: dominant negative Smad3; SMAD7: Smad7).
αSMA by TGFβ in this system. Blocking ERK1,2 or p38β by specific kinase inhibitors or by adenoviral delivery of interfering mutants of the p38 signalling cascade, largely prevented αSMA synthesis and the incorporation of αSMA into actin fibres upon TGFβ stimulation. Similarly, inhibition of the Smad signalling system also blocked αSMA expression in our tubular cells.
These results contribute to accumulating evidence obtained in different model systems of TGFβ-induced EMT that suggest that several parallel signalling systems cooperate in order to execute the complex cellular program of EMT. A microarray-based screen of transcriptional profiles of TGFβ-induced EMT in human keratinocytes revealed that different cellular 'response modules' are regulated by different signalling cascades. For example, ERK1,2 plays an important role in TGFβ-directed cell motility and disruption of adherens junctions, whereas the Smad pathway regulates the expression of several mesenchymal markers [5] . Our results, similar to recent reports [25] , demonstrate that parallel signalling pathways are also involved in regulating single components of EMT, such as αSMA expression.
ERK1,2 activation has been shown to contribute to TGFβ-induced EMT in different epithelial cells, including renal tubular cells [13] . TGFβ-induced αSMA protein synthesis was blocked by the specific MEK1 inhibitor PD98059 in our renal tubular cells, as well. Blocking ERK1,2 activation also prevented the appearance of cellular αSMA staining, demonstrating the importance of the ERK1,2 cascade in the regulation of epithelialmesenchymal transition. Interestingly, prolonged activation of the ERK1,2 cascade by infecting tubular cells with adenoviral vectors expressing CA MEK1 mutant did not induce αSMA expression, suggesting that activation of ERK1,2 alone is not sufficient to trigger the complex cellular program. Alternatively, we cannot rule out the possibility that the abiphasic activation pattern is necessary for the specific cellular response to ERK1,2 activation and this is not well simulated by the prolonged ERK1,2 activation induced by the mutant MEK1.
We have shown here that TGFβ induced phosphorylation of p38 MAPK. Furthermore, blocking p38 MAPK by the specific inhibitor SB 203580 inhibited αSMA protein synthesis and actin fibre formation induced by TGFβ. Also, p38 MAPK is readily activated by TGFβ in different cells and it is thought to mediate important Smad-independent TGFβ responses. In addition, p38 has been shown to contribute to the regulation of αSMA in smooth muscle cells [18] . Furthermore, p38 MAPK has been shown to contribute to the regulation of EMT in different cells [10, 14] . Recently p38 MAPK has been implicated in TGFβ-induced EMT in renal tubular cells [13] . The molecular details of how TGFβ-induced p38 MAPK could potentially regulate EMT or αSMA expression in renal tubular cells, however, have not yet been elucidated.
The signalling specificity of p38 MAPK may, at least in part, be determined by the specific isoforms expressed and/or activated in a given cell type [16] . Our results suggest that p38β and p38δ, but not p38α or p38γ, are expressed in our renal tubular cells. Using adenoviral gene delivery, we have demonstrated that TGFβ induces αSMA expression primarily via the MKK6-p38β pathway. Bhowmick et al. have also implicated p38β in the regulation of EMT induced by TGFβ in NMuMG epithelial cells [14] . It has also been suggested that this isoform may inhibit apoptosis, whereas p38α facilitates programmed cell death in tumour cells [26] . Based on this information, one could postulate that the expression pattern of the p38 MAPK isoforms could possibly determine if TGFβ-induced p38 activation results in apoptosis or in a different set of cellular responses, including EMT, in epithelial cells.
The Smad family of signalling proteins has also been implicated in the regulation of TGFβ-induced EMT [8, 10] . Our results suggest that in renal tubular cells, both Smad2 and Smad3 contribute to αSMA expression induced by TGFβ. Blocking R-Smad activation by over-expressing Smad7 or Smad3 activation using DN Smad3 inhibited αSMA synthesis almost completely. Similar to our findings, Valcourt et al. have recently presented data suggesting that both Smad2 and Smad3 are required for TGFβ-induced EMT in human and mouse epithelial cells [10] . Furthermore, Phanish et al. have demonstrated that the TGFβ-induced up-regulation of αSMA expression was dependent on both R-Smad proteins in transformed proximal tubular cells [9] .
Previous studies have shown that the first 125 base pairs of the SMA promoter drive maximal reporter expression in smooth muscle cells. This region contains two CC(A/T)richGG cis-acting elements and a recently described TGFβ control element (TCE). The CArG motifs are binding sites for the transcriptional activator serum response factor (SRF), whereas the TCE likely interacts with Kruppel factor-like transactivators. Earlier we found that TGFβ inducibility of the SMA promoter in our tubular cells showed similar structural requirements [12] . Recently, Hu et al. described a Smad-binding element (SBE) [27] at −522 to −513 from the transcriptional start site. It is possible that this element contributes to the observed effect of TGFβ on SMA expression in renal tubular cells. Further studies are needed, however, to establish this possibility.
Inhibition of both ERK1,2, p38 MAPK, and the Smad pathway resulted in an almost complete blockage of αSMA synthesis in our experiments. On the other hand, isolated and prolonged activation of neither ERK1,2 nor p38 was sufficient to induce αSMA expression. Our experiments were not designed to study the complex organizational pattern of these individual signalling pathways; however, we speculate that these parallel pathways cooperate to regulate the activity and/or the expression of downstream effectors. Multiple mechanisms for crosstalk between ERK1,2, p38 MAPK, and the Smad pathway have been described. Both ERK1,2 [28] and p38 [23] have been reported to contribute to Smad activation. In our experiments, Smad phosphorylation preceded both ERK1,2 and p38 MAPK activation. Furthermore, MAPK inhibitors did not block the TGFβ-induced Smad phosphorylation (not shown). Previous reports, including work by Leivonen and Kähäri, have demonstrated that the p38 MAPK [29] [30] [31] cascades can be activated via Smad-dependent mechanisms. We are not aware of findings suggesting Smad-dependent ERK activation. On the other hand, we did not see reduced MAPK activation in cells overexpressing Smad7, the inhibitory Smad protein. These preliminary results together provide argument against a hierarchical model of these signalling cascades and we propose that these three pathways are organized to cooperate in a parallel system. Further work, however, is needed to dissect this important aspect of this complex signalling system.
Better understanding of the details of the complex signalling systems regulating EMT may offer opportunities for targeted pharmacological interventions to halt this process that is one of the core mechanisms of tubulo-interstitial fibrosis. Dissecting the specific role played by different p38 MAPK isoforms may be of clinical significance in this respect as isoform-specific p38 inhibitors are already being designed for potential use under different clinical conditions.
In summary, we report here that both ERK1,2, p38β MAPK, and Smad2 and Smad3 are required for the TGFβ-induced induction of αSMA expression in renal proximal tubular cells during EMT. Based on our results, we suggest that the cooperation of parallel signalling pathways is necessary to elicit this cellular response. Further experiments to elucidate the molecular mechanisms involved in the transcriptional regulation of αSMA during TGFβ-induced EMT in renal proximal tubular cells are under way in our laboratories.
